VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Levis on the Challenges of Treating FLT3-ITD AML

Mark J. Levis, MD, PhD
Published: Wednesday, Nov 27, 2013

Mark J. Levis, MD, PhD, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses the difficulty of treating a patient with a FLT3-ITD mutation in acute myeloid leukemia (AML).

While an AML patient with a low white blood cell count can be maintained with transfusions and antibiotics, the population of patients with a FLT3-ITD mutation are difficult to palliate, Levis says.

The majority of patients with a high white blood cell count and a FLT3-ITD mutation can be treated into remission but they will eventually relapse. The hope is that these patients can remain in remission long enough to be able to get a transplant.

Mark J. Levis, MD, PhD, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses the difficulty of treating a patient with a FLT3-ITD mutation in acute myeloid leukemia (AML).

While an AML patient with a low white blood cell count can be maintained with transfusions and antibiotics, the population of patients with a FLT3-ITD mutation are difficult to palliate, Levis says.

The majority of patients with a high white blood cell count and a FLT3-ITD mutation can be treated into remission but they will eventually relapse. The hope is that these patients can remain in remission long enough to be able to get a transplant.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x